This innovative test leverages advanced methylation profiling technology, a globally accepted method, to identify tumor DNA fragments in the blood, providing a simple and non-invasive way for cancer screening, Reliance Industries announced in a press release on Monday.
CancerSpot works by analysing a simple blood sample and utilizing a proprietary genome sequencing and analysis process to detect DNA methylation signatures that are indicative of cancer.
The test’s design draws on robust signatures from Indian cohorts, ensuring its relevance across different ethnicities worldwide. As a result, CancerSpot offers a convenient and effective solution for proactive cancer screening, according to Reliance Industries.
“Reliance is committed to pioneering breakthroughs that reshape the future of medicine in service of humanity. Cancer in India is emerging as a major cause of morbidity and mortality. It is a source of heavy financial, social, and psychological burden on patients, families, and communities. Strand’s novel cancer early detection test exemplifies our vision of delivering transformative healthcare solutions. We are committed to utilizing the power of genomics to advance healthcare and wellness, improving lives in India and the rest of the world,”said Isha Ambani Piramal, Member of the Board, Reliance Industries.
During the inauguration of Strand’s new Genomics Diagnostics & Research Centre in Bengaluru, Dr. Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences, stressed on the importance of early detection in the fight against cancer. “Early warning is the key to battle cancer ─ and win it. We are proud to launch an accessible early cancer detection test that will enable people to stay ahead of cancer. Over our 24-year history, Strand has been a pioneer in genomics, and this is another FIRST for India resulting from a rigorous multi-year research study,” Dr. Hariharan said.The newly opened 33,000 square feet facility is equipped with genomics laboratories, featuring the latest sequencing technologies and workflows to promote collaboration among bioinformatics experts, molecular biologists, and clinical teams.
Strand’s new Genomics Diagnostics & Research Centre aims to accelerate efforts in developing new diagnostic solutions and life-saving research, Reliance Industries said.
